SCHEMBL20148918

SCHEMBL20148918

CS(=O)(=O)c1n[nH]c(-c2nc(Cc3ccccc3F)c3ccccn23)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.40
PDE5A O76074 4/20 0.34
GUCY1A1 Q02108 6/20 0.33
GUCY1B1 Q02153 6/20 0.33
KCNH2 Q12809 2/20 0.33
HIF1A Q16665 1/20 0.33
EPAS1 Q99814 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
AKR1B1 P15121 1/20 0.32
PDE4A P27815 2/20 0.32
PDE4B Q07343 2/20 0.32
PDE4C Q08493 2/20 0.32
PDE4D Q08499 2/20 0.32
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31
HPGD P15428 1/20 0.31
TSHR P16473 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20148879 0.85 AR (0.41) ARPDE5AGUCY1A1GUCY1B1KCNH2
SCHEMBL20141194 0.82 HIF1A (0.37) HIF1AEPAS1
SCHEMBL20148902 0.80 HIF1A (0.43) ARPDE5AGUCY1A1GUCY1B1KCNH2
SCHEMBL21564207 0.80 AR (0.39) ARPDE5AGUCY1A1GUCY1B1KCNH2
SCHEMBL20148877 0.80 AR (0.39) ARPDE5AGUCY1A1GUCY1B1KCNH2
SCHEMBL25791468 0.80 AR (0.40) ARPDE5AGUCY1A1GUCY1B1KCNH2
SCHEMBL20148917 0.80 AR (0.40) ARPDE5AGUCY1A1GUCY1B1KCNH2
SCHEMBL21564211 0.78 AR (0.38) ARPDE5AGUCY1A1GUCY1B1KCNH2
SCHEMBL20148878 0.76 PIM1 (0.43) ARPDE5AGUCY1A1GUCY1B1KCNH2
SCHEMBL21787231 0.73 AR (0.36) ARPDE5AGUCY1A1GUCY1B1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3538096-B1 TREATMENT OF CNS DISEASES WITH SGC STIMULATORS TISENTO THERAPEUTICS INC (US) 2024-02-28 EP disclosed
US-20230381153-A1 TREATMENT OF CNS DISEASES WITH sGC STIMULATORS TISENTO THERAPEUTICS INC. 2023-11-30 US disclosed
US-11690828-B2 Treatment of CNS diseases with sGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
US-20190343813-A1 TREATMENT OF CNS DISEASES WITH sGC STIMULATORS CYCLERION THERAPEUTICS, INC. (US) 2019-11-14 US disclosed
WO-2018111795-A2 USE OF SGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-06-21 WO disclosed
WO-2018089328-A1 TREATMENT OF CNS DISEASES WITH SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190343813-A1 TREATMENT OF CNS DISEASES WITH sGC STIMULATORS GUCY1A2, GUCY1B2, PDE2A AR 4768/4885PDE5A 11/4885GUCY1A1 4/4885
US-11690828-B2 Treatment of CNS diseases with sGC stimulators GUCY1A2, GUCY1B2, PDE2A AR 4768/4885PDE5A 11/4885GUCY1A1 4/4885
US-20230381153-A1 TREATMENT OF CNS DISEASES WITH sGC STIMULATORS GUCY1A2, GUCY1B2, PDE2A AR 4768/4885PDE5A 11/4885GUCY1A1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.